Oxycodone and Metabolites, Urine
Oxycodone is a semisynthetic opioid agonist derived from thebaine that is typically used in combination with non-opioid analgesics such as acetaminophen, ibuprofen, or aspirin. Oxycodone is considered equipotent with morphine. Typical routes of administration include oral, intramuscular, intravenous, subcutaneous, and rectal. The major metabolites of oxycodone are noroxycodone and oxymorphone, which is biologically active and significantly augments the therapeutic effects of the drug oxycodone. The primary metabolic enzyme responsible for production of noroxycodone is CYP3A4, whereas the primary enzyme involved in production of oxymorphone is CYP2D6. Oxymorphone is subsequently metabolized to noroxymorphone by a reaction mediated primarily by CYP3A4. Inhibitors of CYP3A4 can lead to dose-related toxicity while inhibitors of CYP2D6 can attenuate the response to oxycodone. Oxycodone, noroxycodone and oxymorphone are excreted into the urine as free drug and as glucuronide conjugates. The half-life of oxycodone is 3-6 hours.
Approximately 72% of a single oral dose is eliminated in the urine within 48 hours. Actual elimination depends on factors such as drug formulation dose, dose frequency, clinical status and pharmacokinetics of the individual patient.
Common side effects: respiratory depression, sedation, nausea, vomiting, dizziness, headache, miosis, constipation, urinary retention, and pruritis. Oxycodone can also contribute to the following effects: hypotension, euphoria, mental clouding, amnesia, hostility, irritability, and vivid or disturbing dreams. Can be addictive. Overdose effects include respiratory collapse, cardiac arrest, coma, and possible death.
Oxycodone and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.
- Adherence monitoring
- Drug abuse evaluation
- Toxicity/Overdose assessment
Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Wu A (ed). Tietz Clinical Guide to Laboratory Tests, 4th ed. Philadelphia: WB Saunders; 2006.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
- Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
- Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.